Department of Internal Medicine.
Department of Internal Medicine, Mathers Hospital, Port Jefferson, NY.
J Clin Gastroenterol. 2021;55(10):836-841. doi: 10.1097/MCG.0000000000001484.
Intragastric balloons (IGBs) have been used to bridge the obesity treatment gap with the benefits of being minimally invasive but still required endoscopy. The Elipse IGB is a swallowable balloon that is spontaneously excreted at ∼16 weeks. However, studies are limited by small sample sizes. The authors aim to assess clinically relevant endpoints, namely weight loss outcomes, metabolic profile, balloon tolerability, and adverse events.
A literature search was performed from several databases from inception to July 2020. The pooled means and proportions of our data were analyzed using a random effects model.
Seven studies involving 2152 patients met our eligibility criteria and were included. The mean baseline body mass index ranged from 32.1 to 38.6. The pooled mean difference (MD) in body mass index was 0.88 [confidence interval (CI): 0.58-1.18, I2=98%]. Total body weight loss was 12% (CI: 10.1-14.3, I2=94%) and excess body weight loss was 49.1% (CI: 30.6-67.5, I2=97%). The MD in waist circumference was 0.89 (CI: 0.72-1.05, I2=53%). MD in triglyceride level was 0.66 (CI: 0.21-1.1, I2=96%). Pooled early deflation rate was 1.8% (CI: 0.6-5.1, I2=74%). Our study also showed that the Elipse balloon was associated with less adverse events when compared with other IGBs.
This meta-analysis demonstrates that the Elipse intragastric balloon is a safe, effective, and tolerable device for weight loss and obesity with a minimal side effect profile.
胃内球囊（IGB）已被用于弥合肥胖治疗差距，其优势为微创，但仍需进行内镜检查。Elipse IGB 是一种可吞咽的球囊，会在大约 16 周时自然排出。然而，这些研究受到样本量小的限制。作者旨在评估临床相关终点，即体重减轻的结果、代谢特征、球囊耐受性和不良事件。
从几个数据库进行了文献检索，检索时间从建库至 2020 年 7 月。使用随机效应模型对我们数据的汇总均值和比例进行分析。
有 7 项研究符合纳入标准，共纳入 2152 例患者。平均基线体重指数范围为 32.1 至 38.6。体重指数的汇总平均差异（MD）为 0.88[置信区间（CI）：0.58-1.18，I²=98%]。总体体重减轻 12%（CI：10.1-14.3，I²=94%），多余体重减轻 49.1%（CI：30.6-67.5，I²=97%）。腰围 MD 为 0.89（CI：0.72-1.05，I²=53%）。甘油三酯水平 MD 为 0.66（CI：0.21-1.1，I²=96%）。早期充气不足的发生率为 1.8%（CI：0.6-5.1，I²=74%）。我们的研究还表明，与其他 IGB 相比，Elipse 球囊与较少的不良事件相关。
这项荟萃分析表明，Elipse 胃内球囊是一种安全、有效且耐受良好的减肥和肥胖治疗装置，具有最小的副作用。
